Paolo Lausi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Paolo Lausi has a total of 87 co-authors. Here are the top co-authors by number of shared publications:
- Enrico Ruffini
Department of Surgical Science, Section of Thoracic Surgery, University of Torino, 10126 Torino, Italy
11 shared publications - Pier Luigi Filosso
Division of Thoracic Surgery, Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, 41121 Modena, Italy
11 shared publications - Alberto Oliaro
Department of Thoracic Surgery, University of Turin, San Giovanni Battista Hospital, Turin, Italy
10 shared publications - Francesco Ardissone
University of Turin, San Luigi Hospital
6 shared publications - Francesco Guerrera
Department of Cardio-Thoracic and Vascular Surgery, Azienda Ospedaliera-Universitaria Città Della Salute e Della Scienza di Torino, 10126 Torino, Italy
5 shared publications Piero Borasio
Department of Clinical and Biological Sciences, Thoracic Surgery Unit, University of Turin, San Luigi Hospital, 10043 Orbassano, Turin, Italy
5 shared publications
Latest Publications
- 1 February 2024
- Published by Edizioni Minerva Medica in Minerva Surgery
- Vol. 79 (1)
Energy devices versus electrocoagulation in video-assisted thoracoscopic lobectomy: a propensity-match cohort study
Article: Energy devices versus electrocoagulation in video-assisted thoracoscopic lobectomy: a propensity-match cohort study - Minerva Surgery 2023 May 23 - Minerva Medica - Journals
- 1 February 2024
- Published by Edizioni Minerva Medica in Minerva Surgery
- Vol. 79 (1)
Energy devices versus electrocoagulation in video-assisted thoracoscopic lobectomy: a propensity-match cohort study
Article: Energy devices versus electrocoagulation in video-assisted thoracoscopic lobectomy: a propensity-match cohort study - Minerva Surgery 2023 May 23 - Minerva Medica - Journals
- 1 January 2018
- Published by AME Publishing Company in Shanghai Chest
- Vol. 2 (4) , 23
Minimally-invasive surgery for non-thymomatous myasthenia gravis
Myasthenia gravis (MG) is one of the most common disorders of the neuromuscular transmission, with a wide variation in clinical severity. A recent randomized trial has demonstrated that thymectomy is effective in achieving MG symptoms improvement and definitive patient’s complete stable remission (CSR). Significant debate however continues concerning the ideal surgical approach for thymectomy. Thymic gland is located into the anterior mediastinum, but an extreme anatomical thymic variability has also been described, since ectopic thymic islands may be found in 32–98% of patients in which an extended transternal thymectomy is performed. The recent advent of minimally-invasive operations has extended the indication for thymectomy in MG patients, achieving comparable results in terms of CSR with more aggressive approaches. Thymectomy in non-thymomatous (NT) MG patients may potentially be a morbid surgical intervention, being performed in young and fragile patients. The risk of developing postoperative complications (generally respiratory) is high. Therefore, the optimal surgical approach should take into account these risks and should be chosen through a reduced operative and anesthesia time, avoiding long periods of artificial ventilation as well as painful surgical incisions. The aim of this editorial is to describe MIT results, compared to the classical extended trans-sternal thymectomy.
- 1 January 2018
- Published by AME Publishing Company in Shanghai Chest
- Vol. 2 (4) , 23
Minimally-invasive surgery for non-thymomatous myasthenia gravis
Myasthenia gravis (MG) is one of the most common disorders of the neuromuscular transmission, with a wide variation in clinical severity. A recent randomized trial has demonstrated that thymectomy is effective in achieving MG symptoms improvement and definitive patient’s complete stable remission (CSR). Significant debate however continues concerning the ideal surgical approach for thymectomy. Thymic gland is located into the anterior mediastinum, but an extreme anatomical thymic variability has also been described, since ectopic thymic islands may be found in 32–98% of patients in which an extended transternal thymectomy is performed. The recent advent of minimally-invasive operations has extended the indication for thymectomy in MG patients, achieving comparable results in terms of CSR with more aggressive approaches. Thymectomy in non-thymomatous (NT) MG patients may potentially be a morbid surgical intervention, being performed in young and fragile patients. The risk of developing postoperative complications (generally respiratory) is high. Therefore, the optimal surgical approach should take into account these risks and should be chosen through a reduced operative and anesthesia time, avoiding long periods of artificial ventilation as well as painful surgical incisions. The aim of this editorial is to describe MIT results, compared to the classical extended trans-sternal thymectomy.
- Open Access
- 1 April 2015
- Vol. 7 (2) , S163-S171-S171
Multidisciplinary management of advanced lung neuroendocrine tumors
Multidisciplinary management of advanced lung neuroendocrine tumors
- 1 April 2015
- Vol. 7 (2) , S163-S171-S171
Open AccessMultidisciplinary management of advanced lung neuroendocrine tumors
Multidisciplinary management of advanced lung neuroendocrine tumors
- Open Access
- 12 November 2014
- Published by Oxford University Press (OUP) in European Journal of Cardio-Thoracic Surgery
- Vol. 47 (6) , 1037-1043
Exploring Stage I non-small-cell lung cancer: development of a prognostic model predicting 5-year survival after surgical resection†
Despite impressive results in diagnosis and treatment of non-small-cell lung cancer (NSCLC), more than 30% of patients with Stage I NSCLC die within 5 years after surgical treatment. Identification of prognostic factors to select patients with a poor prognosis and development of tailored treatment strategies are then advisable. The aim of our study was to design a model able to define prognosis in patients with Stage I NSCLC, submitted to surgery with curative intent. A retrospective analysis of two surgical registries was performed. Predictors of survival were investigated using the Cox model with shared frailty (accounting for the within-centre correlation). Candidate predictors were: age, gender, smoking habit, morbidity, previous malignancy, Eastern Cooperative Oncology Group performance status, clinical N stage, maximum standardized uptake value (SUVmax), forced expiratory volume in 1 s, carbon monoxide lung diffusion capacity (DLCO), extent of surgical resection, systematic lymphadenectomy, vascular invasion, pathological T stage, histology and histological grading. The final model included predictors with P < 0.20, after a backward selection. Missing data in evaluated predictors were multiple-imputed and combined estimates were obtained from 10 imputed data sets. Analysis was performed on 848 consecutive patients. The median follow-up was 48 months. Two hundred and nine patients died (25%), with a 5-year overall survival (OS) rate of 74%. The final Cox model demonstrated that mortality was significantly associated with age, male sex, presence of cardiac comorbidities, DLCO (%), SUVmax, systematic nodal dissection, presence of microscopic vascular invasion, pTNM stage and histological grading. The final model showed a fair discrimination ability (C-statistic = 0.69): the calibration of the model indicated a good agreement between observed and predicted survival. We designed an effective prognostic model based on clinical, pathological and surgical covariates. Our preliminary results need to be refined and validated in a larger patient population, in order to provide an easy-to-use prognostic tool for Stage I NSCLC patients.
- 12 November 2014
- Published by Oxford University Press (OUP) in European Journal of Cardio-Thoracic Surgery
- Vol. 47 (6) , 1037-1043
Open AccessExploring Stage I non-small-cell lung cancer: development of a prognostic model predicting 5-year survival after surgical resection†
Despite impressive results in diagnosis and treatment of non-small-cell lung cancer (NSCLC), more than 30% of patients with Stage I NSCLC die within 5 years after surgical treatment. Identification of prognostic factors to select patients with a poor prognosis and development of tailored treatment strategies are then advisable. The aim of our study was to design a model able to define prognosis in patients with Stage I NSCLC, submitted to surgery with curative intent. A retrospective analysis of two surgical registries was performed. Predictors of survival were investigated using the Cox model with shared frailty (accounting for the within-centre correlation). Candidate predictors were: age, gender, smoking habit, morbidity, previous malignancy, Eastern Cooperative Oncology Group performance status, clinical N stage, maximum standardized uptake value (SUVmax), forced expiratory volume in 1 s, carbon monoxide lung diffusion capacity (DLCO), extent of surgical resection, systematic lymphadenectomy, vascular invasion, pathological T stage, histology and histological grading. The final model included predictors with P < 0.20, after a backward selection. Missing data in evaluated predictors were multiple-imputed and combined estimates were obtained from 10 imputed data sets. Analysis was performed on 848 consecutive patients. The median follow-up was 48 months. Two hundred and nine patients died (25%), with a 5-year overall survival (OS) rate of 74%. The final Cox model demonstrated that mortality was significantly associated with age, male sex, presence of cardiac comorbidities, DLCO (%), SUVmax, systematic nodal dissection, presence of microscopic vascular invasion, pTNM stage and histological grading. The final model showed a fair discrimination ability (C-statistic = 0.69): the calibration of the model indicated a good agreement between observed and predicted survival. We designed an effective prognostic model based on clinical, pathological and surgical covariates. Our preliminary results need to be refined and validated in a larger patient population, in order to provide an easy-to-use prognostic tool for Stage I NSCLC patients.
- 1 August 2014
- Published by Elsevier in Thoracic Surgery Clinics
- Vol. 24 (3) , 327-332
Thymic Neuroendocrine Tumors
- 1 August 2014
- Published by Elsevier in Thoracic Surgery Clinics
- Vol. 24 (3) , 327-332
Thymic Neuroendocrine Tumors
- 1 February 2014
- Published by Elsevier in Lung Cancer
- Vol. 83 (2) , 126-132
Historical perspectives: The evolution of the thymic epithelial tumors staging system
- 1 February 2014
- Published by Elsevier in Lung Cancer
- Vol. 83 (2) , 126-132
Historical perspectives: The evolution of the thymic epithelial tumors staging system
- Open Access
- 17 February 2013
- Published by Oxford University Press (OUP) in Interactive CardioVascular and Thoracic Surgery
- Vol. 16 (5) , 661-666
Efficacy and safety of human fibrinogen–thrombin patch (TachoSil®) in the treatment of postoperative air leakage in patients submitted to redo surgery for lung malignancies: a randomized trial
Previous studies of the human fibrinogen–thrombin patch TachoSil® for air leak management in thoracic surgery have excluded patients undergoing redo surgery, a group at high risk of persistent air leaks. This is the first study to assess TachoSil® in patients undergoing redo surgery. Patients who had undergone pulmonary resection for primary lung cancer or lung metastasis and were scheduled for completion lobectomy plus lymphadenectomy due to tumour recurrence were eligible. After complete lobectomy, patients with intraoperative Macchiarini grade 3 air leaks (or >30% of the tidal volume at plethysmographic assessment) were randomized to receive either TachoSil® or further lung parenchymal stapling/suturing procedures according to standard surgical practice. A total of 24 patients were randomized to TachoSil® (n = 13) or standard treatment (n = 11). Mean duration of surgery was significantly shorter in the TachoSil® group than in the standard group (3.6 vs 4.0 h; P = 0.023). The mean duration of air leaks was also significantly reduced in the TachoSil® group (4.7 vs 10.0 days; P < 0.001), and the removal of both the first and the second chest tubes occurred earlier (mean 3.8 vs 5.5 days; P = 0.005; and 6.1 vs 10.8 days; P < 0.001, respectively). TachoSil® was also effective in reducing persistent (≥9 days) air leaks (1 vs 7 patients; P = 0.008). There were no significant differences between groups in other postoperative complications. Mean length of hospital stay was significantly shorter in TachoSil®-treated patients (6.9 vs 9.5 days; P < 0.001). TachoSil® was superior to standard stapling and suturing aerostatic techniques in reducing postoperative air leaks in patients undergoing redo thoracic surgery.
- 17 February 2013
- Published by Oxford University Press (OUP) in Interactive CardioVascular and Thoracic Surgery
- Vol. 16 (5) , 661-666
Open AccessEfficacy and safety of human fibrinogen–thrombin patch (TachoSil®) in the treatment of postoperative air leakage in patients submitted to redo surgery for lung malignancies: a randomized trial
Previous studies of the human fibrinogen–thrombin patch TachoSil® for air leak management in thoracic surgery have excluded patients undergoing redo surgery, a group at high risk of persistent air leaks. This is the first study to assess TachoSil® in patients undergoing redo surgery. Patients who had undergone pulmonary resection for primary lung cancer or lung metastasis and were scheduled for completion lobectomy plus lymphadenectomy due to tumour recurrence were eligible. After complete lobectomy, patients with intraoperative Macchiarini grade 3 air leaks (or >30% of the tidal volume at plethysmographic assessment) were randomized to receive either TachoSil® or further lung parenchymal stapling/suturing procedures according to standard surgical practice. A total of 24 patients were randomized to TachoSil® (n = 13) or standard treatment (n = 11). Mean duration of surgery was significantly shorter in the TachoSil® group than in the standard group (3.6 vs 4.0 h; P = 0.023). The mean duration of air leaks was also significantly reduced in the TachoSil® group (4.7 vs 10.0 days; P < 0.001), and the removal of both the first and the second chest tubes occurred earlier (mean 3.8 vs 5.5 days; P = 0.005; and 6.1 vs 10.8 days; P < 0.001, respectively). TachoSil® was also effective in reducing persistent (≥9 days) air leaks (1 vs 7 patients; P = 0.008). There were no significant differences between groups in other postoperative complications. Mean length of hospital stay was significantly shorter in TachoSil®-treated patients (6.9 vs 9.5 days; P < 0.001). TachoSil® was superior to standard stapling and suturing aerostatic techniques in reducing postoperative air leaks in patients undergoing redo thoracic surgery.
- Open Access
- 1 March 2012
- Published by Oxford University Press (OUP) in European Journal of Cardio-Thoracic Surgery
- Vol. 41 (3) , 628-629
Re: Survival after extended thymectomy for thymoma
Since the beginning of time, humans have desired to ‘know before’. Greeks defined this practice πρόγνωση (pro-gnosis, literally fore-knowing, foreseeing). In cancer management, the practice aims to identify the so-called prognostic factors. Different cancers have different prognostic factors, and a prognostic factor which is valid for frequent neoplasms may not be applicable in less frequent malignancies such as thymic neoplasms in which the literature consists almost exclusively of retrospective single institution series, extending over multiple decades, using different outcome measures and definitions.
- 1 March 2012
- Published by Oxford University Press (OUP) in European Journal of Cardio-Thoracic Surgery
- Vol. 41 (3) , 628-629
Open AccessRe: Survival after extended thymectomy for thymoma
Since the beginning of time, humans have desired to ‘know before’. Greeks defined this practice πρόγνωση (pro-gnosis, literally fore-knowing, foreseeing). In cancer management, the practice aims to identify the so-called prognostic factors. Different cancers have different prognostic factors, and a prognostic factor which is valid for frequent neoplasms may not be applicable in less frequent malignancies such as thymic neoplasms in which the literature consists almost exclusively of retrospective single institution series, extending over multiple decades, using different outcome measures and definitions.
- 1 December 2011
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 37 (12) , 1093-1098
Preliminary results of a new small-bore percutaneous pleural catheter used for treatment of malignant pleural effusions in ECOG PS 3–4 patients
- 1 December 2011
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 37 (12) , 1093-1098
Preliminary results of a new small-bore percutaneous pleural catheter used for treatment of malignant pleural effusions in ECOG PS 3–4 patients